Topical Phenytoin for Management of Gingival Recession
ConditionGingival Recession
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorCairo University
About this trial
Gingival recession (GR) is a term that describes the displacement of the gingival margin apical to the cemento-enamel junction (CEJ) of a tooth. The gold standard of GR treatment is surgical coverage through coronally advanced flap with subepithelial connective tissue graft (CAF+SCTG) (3). But, the need for a non-invasive technique for managing GR has not been frequently addressed.
Phenytoin (PHT), used as an anti-seizure medication, has an established side effect of causing drug-influenced gingival enlargement. Its stimulatory effects on soft tissue metabolism suggested PHT to be tested topically for its effectiveness in wound healing. However, none of the previous studies that investigated topical phenytoin has assessed gingival recession; except for a case series.
Eligibility criteria
Qualifiers
Patients having gingival recession types RT1 and RT2
Patients refusing surgical treatment options of their gingival recession.
Disqualifiers
Patients who underwent periodontal surgery in the affected teeth.
Patients with sensitivity to the medication used in the study.
Patients with systemic problems or administering drugs which could affect their periodontium or healing.
Pregnant or lactating women.
Trial design
Treatments tested in this trial
- phenytoin cream
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov